西达本胺联合雷利度胺和地塞米松治疗多发性骨髓瘤的临床研究  

Clinical Analysis of Chidamide Combined with Lenalidomide and Dexamethasone in Treatment of Patients with Multiple Myeloma

作　　者：宫敬智 杨雷[1] 白培清 孙小燕 金建刚 张维莲[1] 郜小岳 秦玉柱 GONG Jing-zhi;YANG Lei;BAI Pei-qing;SUN Xiao-yan;JIN Jian-gangZHANG Wei-lian;GAO Xiao-yue;QIN Yu-zhu(Department of Hematopathology,81 Army Group Hospital of PLA,Zhangjiakou,Hebei 075000,China;Department of Nephrology,81 Army Group Hospital of PLA,Zhangjiakou,Hebei 075000,China;Department of Internal Medicine,the First Hospital of Zhangjiakou,Zhangjiakou,Hebei 075000,China)

机构地区：[1]中国人民解放军陆军第八十一集团军医院血液内科,河北张家口075000 [2]中国人民解放军陆军第八十一集团军医院肾内科,河北张家口075000 [3]张家口市第一医院内科,河北张家口075000

出　　处：《解放军医药杂志》2020年第2期36-39,共4页Medical & Pharmaceutical Journal of Chinese People’s Liberation Army

基　　金：河北省卫生厅科研基金项目(20181552);张家口市科学技术研究与发展计划项目(1712001D)

摘　　要：目的探讨西达本胺联合雷利度胺和地塞米松治疗多发性骨髓瘤的临床价值。方法选取2016年4月-2019年4月本院收治的多发性骨髓瘤患者62例,根据治疗方案不同分为观察组和对照组,每组31例。对照组给予雷利度胺和地塞米松,观察组在对照组基础上加用西达本胺。对比2组患者的临床疗效、实验室指标及不良反应发生率。结果观察组总有效率显著高于对照组(P<0.05)。2组治疗前血红蛋白、血清肌酐、血清M蛋白、骨髓浆细胞比较差异无统计学意义(P>0.05);与治疗前比较,2组治疗后血红蛋白升高,血清肌酐、血清M蛋白、骨髓浆细胞降低,且观察组上述指标优于对照组(P<0.05)。观察组总不良反应发生率低于对照组(P<0.05)。结论西达本胺联合雷利度胺和地塞米松可抑制多发性骨髓瘤患者血清M蛋白及骨髓浆细胞升高,改善贫血、肾功能不全症状,临床疗效及药物安全性较雷利度胺和地塞米松治疗更高。Objective To investigate clinical value of Chidamide combined with Lenalidomide and Dexamethasone in treatment of patients with multiple myeloma.Methods A total of 62 patients with multiple myeloma admitted during April 2016 and April 2019 were divided into observation group and control group(n=31 in each group)according to different therapeutic methods.Control group was treated with Lenalidomide and Dexamethasone,while observation group was supplemented with Chidamide on the basis of treatment for control group.Clinical efficacy,laboratory indexes and incidence rate of adverse reactions were compared between two groups.Results The total effective rate in observation group was significantly higher than that in control group(P<0.05).There were no significant differences in levels of hemoglobin,serum creatinine,serum M protein and bone marrow plasmacyte before treatment in two groups(P>0.05).After treatment,hemoglobin levels were significantly increased,and levels of serum creatinine,serum M protein and bone marrow plasma cells were significantly decreased compared with those before treatment in two groups,and the above indexes in observation group were superior to those in control group(P<0.05).Incidence rate of complications in observation group was lower than that in control group(P<0.05).Conclusion Chidamide combined with Lenalidomide and Dexamethasone may inhibit increase of serum M protein and bone marrow plasmacyte in multiple myeloma and improve symptoms of anemia and renal insufficiency.Its clinical efficacy and safety are higher than those by Lenalidomide and Dexamethasone.

关 键 词：多发性骨髓瘤 西达本胺 雷利度胺 地塞米松 浆细胞 血红蛋白测定 

分 类 号：R733.3[医药卫生—肿瘤]